Loading clinical trials...
Loading clinical trials...
Phase 1-2a Safety, Tolerability, and Pharmacodynamics Controlled Study of NOV-001 in Healthy Volunteers and Patients With Enteric Hyperoxaluria
Conditions
Interventions
NOV-001
NB1000S
+2 more
Locations
20
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Mayo Clinic
Scottsdale, Arizona, United States
Advanced Urology Institute
Daytona Beach, Florida, United States
Prohealth Research Center
Doral, Florida, United States
Florida Urology Partners
Tampa, Florida, United States
Georgia Clinical Research
Lawrenceville, Georgia, United States
Start Date
June 2, 2021
Primary Completion Date
November 30, 2022
Completion Date
April 6, 2023
Last Updated
May 17, 2023
NCT00104325
NCT07118891
NCT01399385
NCT07295717
NCT03807401
NCT07271693
Lead Sponsor
Novome Biotechnologies Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions